NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells $834,486.84 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the sale, the insider now directly owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. This represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total value of $213,420.60.

NewAmsterdam Pharma Stock Down 4.0 %

NAMS stock opened at $23.68 on Wednesday. The stock has a 50-day simple moving average of $18.82 and a two-hundred day simple moving average of $18.61. NewAmsterdam Pharma has a twelve month low of $8.90 and a twelve month high of $26.35.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NAMS. Needham & Company LLC restated a “buy” rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, November 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Piper Sandler restated an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Buy” and an average target price of $33.80.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after purchasing an additional 1,399 shares during the period. Banque Cantonale Vaudoise purchased a new stake in shares of NewAmsterdam Pharma in the second quarter worth $38,000. Quarry LP raised its position in shares of NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after buying an additional 6,247 shares in the last quarter. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the period. Finally, Bellevue Group AG purchased a new position in NewAmsterdam Pharma during the third quarter worth about $128,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.